A Single Dose, 2-Period, Cross-Over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil.

Trial Profile

A Single Dose, 2-Period, Cross-Over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2010

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Dec 2010 Actual initiation date changed from Mar 2008 to Mar 2009 as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Actual initiation date (Mar 2008), actual patient number (36) added as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top